United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery
September 04, 2018 at 07:54 AM EDT
Under the deal with MannKind Corp., Silver Spring's United Therapeutics will be responsible for global development, regulatory and commercial activities for the dry power formulation and inhalation delivery of treprostinil, the active ingredient in United Therapeutics' flagship product Remodulin.
